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See Article, pages 377–387Hepatitis B virus (HBV) infection is a major risk fac-
tor for developing hepatocellular carcinoma (HCC),
although other environmental and lifestyle factors,
including hepatitis C virus (HCV) infection, heavy alco-
hol consumption, chronic exposure to aﬂatoxins and
tobacco smoking are considered to be the other associ-
ated risk factors. HBV infection, which is involved in
53% of HCC cases, aﬀects more than 350 million people
and is the most deleterious type of viral hepatitis [1].
However, although a causal relationship between HBV
infection and development of HCC has been well-estab-
lished, the molecular mechanisms by which HBV trig-
gers hepatocarcinogenesis are still unclear [2–4].
Besides integration of the viral genome in the host cell
chromosomes and potential activation of cellular sur-
veillance mechanisms, accumulating evidence indicates
that HBV-infected hepatocytes often exhibit altered epi-
genetic status [5–8]. Hence, it has been proposed that the
viral genome and/or viral proteins can interfere with
normal epigenetic mechanisms whose disruption may
promote development of HCC [9,10]. In agreement with
this hypothesis, some evidence suggests that HBV
encoded 17 kDa X-protein (HBx), which is capable of
transactivation and transrepression of both viral and
cellular genes through its direct interaction with several
diﬀerent nuclear transcription factors, may modulate
transcriptional activity of the target genes through epi-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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E-mail address: herceg@iarc.fr (Z. Herceg).genetic modiﬁcations [7,8,11–13]. HBx was found to
upregulate expression of the DNA-methyltransferase
(DNMT) genes (supporting a transcriptional transacti-
vation property of HBx), and thus corresponding
down-regulation of several important cellular genes
was attributed to the DNMT-mediated methylation of
the target genes [11,12]. Transcription transactivation
property of HBx is supported by the fact that HBx inter-
acts with CBP/P300 complex possessing histone acetyl-
transferase activity [14]. A recent study, perhaps
surprisingly, revealed a histone deacetylase (HDAC) as
a direct HBx-interacting partner [13], thus raising the
questions of whether HBx associates with other mem-
bers of the cellular epigenetic machinery and what gov-
erns these interactions.
In their current study, Zheng et al. [15] in this issue of
the Journal use an elegant biochemical approach to
detect interaction of HBx with cellular epigenetic
machinery proteins, unraveling the mechanisms involved
in HBx-mediated epigenetic modiﬁcations and gene reg-
ulation. Using microarray analysis they compared gene-
expression diﬀerences between HBx-overexpressing and
control hepatic cells. Among several genes whose expres-
sion was found to be aﬀected by ectopic HBx-expression,
the authors broadly concentrated on MT1F and IL4R
genes (which were found to be down-regulated), and
IGFBP3 and CDH6 genes among the genes showing
up-regulation. Surprisingly, expressions of these targeted
genes also corresponded with the methylation status of
their respective promoters, indicating that HBx may
aﬀect the methylation status of regulatory regions of
these genes. Possible HBx-mediated up-regulation of
expression of DNMT-genes and thus resultant down-Published by Elsevier B.V. All rights reserved.
Fig. 1. Hypothetical models depicting possible molecular mechanisms by
which HBx deregulate epigenetic states and expression of host genes. (A)
Current understanding of HBx interactions with host cellular gene-
regulatory machinery in unscheduled activation of cellular genes. HBx by
interacting with DNA-bound transcription factors may help recruitment
of histone acetyltransferases and thus exhibit its transactivation function
e.g. IGF3 gene [14]. (B and C) The model based on the ﬁndings presented
by Zheng et al. Binding of HBx to speciﬁc transcription factor(s) may
lead to subsequent recruitment of DNMT3A or HDAC1, resulting in
hypermethylation and heterochromatinization of the promoter region and
gene silencing e.g. MT1F and IL4R genes (B). HBx may hinder with
binding of potential repressor(s) on target gene-promoter and thus
allowing hypomethylation, possible histone acetylation (active chromatin
conformation) and expression of the target gene e.g. IGFBP3 and CDH6
genes (C). TF, transcription factor; HAT, histone acetyltransferase;
MCBP, methyl-cytosine binding protein.
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DNA hypermethylation could explain the hypermethyla-
tion-associated repression of the MT1F and IL4R gene
expression. However, hypomethylation mediated up-reg-
ulation of IGFBP6 and CDH6 genes was still intriguing.
The authors thus argue that the observed increase in
DNMT activity alone cannot account for the unique
and CpG-methylation-based alterations in the transcrip-
tional activities (up- as well as down-regulation) of the
speciﬁc target genes, in HBx transfected cells. They thus
hypothesized that there must be some other cellular
mechanism that triggers cellular chromatin remodeling
and subsequent regionally aberrant DNA methylation.
In order to check this hypothesis, authors took advan-
tage of immunoprecipitation and ChIP techniques. One
would expect that HBx might interact with either histone
acetyltransferases (which by recruitment on the target
gene regulatory sequence, may facilitate histone acetyla-
tion and up-regulation of candidate genes) or with some
DNA-demethylase (which may help to up-regulate can-
didate gene via the observed promoter DNA hypomethy-
lation). Indeed, previous studies reported that HBx
functionally interacts with CBP/p300 (histone acetyl-
transferase) in regulation of CREB-mediated transcrip-
tion [14]. On the contrary, one might expect to ﬁnd it
recruiting a DNA-methyltransferase and/or histone
deacetylase on the promoter region of the HBx-sup-
pressed candidate genes [16]. Hypermethylation of cellu-
lar genes in the presence of HBx, due to DNMT1 and
DNMT3A recruitment on target promoter regions is
known [11,12]. However, in the present work Zheng
et al. focus mainly on HBx interaction with DNMT’s
and HDAC1. Contrary to previous ﬁndings they show
that ectopic expression of HBx in Huh7 and HepG2 cells
was unable to inﬂuence expression of DNMT1,
DNMT3A or DNMT3B. Moreover, they successfully
demonstrate that HBx interacts directly with DNMT1,
DNMT3A and HDAC1. The DNMT3A interaction
was proved to be physiologically relevant as it could also
be found in HCC tissue samples.
Next, the authors addressed the importance of inter-
action between HBx and these epigenetic players. By
employing ChIP and re-ChIP techniques they demon-
strate that ectopic HBx recruits DNMT3A on promot-
ers of the repressed genes (MT1F and IL4R) and that
epigenetic modiﬁcation of these promoters (i.e. hyper-
methylation) takes place speciﬁcally by DNMT3A
recruitment (Fig. 1B). The present ﬁnding is also in
agreement with the previous observation, showing that
HBx speciﬁcally represses insulin-like growth factor-3
expression through DNMT3A-mediated de novo meth-
ylation and by inhibiting SP1 binding via recruiting
methyl-CpG-binding protein 2 (MCBP2) to the newly
methylated SP1 binding element [12]. Hence, in the light
of the present work it can be speculated that HBx-med-
iated repression of the IGF-3 gene may also requirerecruitment of DNMT3A-HBx complex on the IGF-3
promoter region (Fig. 1B).
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three diﬀerent DNMTs. DNMT1 functions as a mainte-
nance enzyme for the premethylation patterns, whereas,
DNMT3A and DNMT3B establish genomic imprinting
during embryogenesis and methylate repetitive
sequences, respectively [16]. It is interesting to note that
disruption of DNMT3A and DNMT3B results in neo-
plastic transformation and tumor progression; thus the
present ﬁnding by Zheng et al. emphasizes the impor-
tance of HBV-mediated DNMT deregulation in HCC
etiology, which may help the design of novel epigenet-
ics-based therapies. Moreover, as DNA methylation is
considered as a primary requirement during gene silenc-
ing, it is possible that as an initial step HBx-DNMT
complexes are recruited to repress a target gene via
DNA methylation, which in turn, may trigger the cas-
cade of transcriptional silencing by targeting methyl-
CpG-binding protein and histone deacetylases.
More strikingly, Zheng et al. report that HBx also
plays a direct role in activation of the up-regulated genes.
They convincingly show that DNMT3A (in the presence
of HBx) dissociates from the promoter region of the up-
regulated genes, thus resulting in observed hypomethyla-
tion and transcriptional activation. However, gene-spe-
ciﬁc diﬀerences are observed in the magnitude of
induction of gene expression and also in levels of
methyl-cytosine, suggesting that HBx, through its bind-
ing to DNMT3A (already associated with diﬀerent
gene-speciﬁc repression-complex subunits), may aﬀect
aﬃnity of DNMT3A to the target regulatory DNA
(Fig. 1C). Using ChIP experiments, authors failed to ﬁnd
recruitment of HBx on the activated target gene-promot-
ers; hence it remains to be investigated, if HBx, could
exhibit its transactivation eﬀect through a mechanism
other than that including recruitment of acetyltransferase
activity (Fig. 1A). Given the vast possibilities of diﬀerent
cellular proteins exhibiting interaction with HBx, it calls
for further investigations to unravel what factors govern
these interactions.
While the epigenetic mechanisms involved in virus-
associated cancers are poorly understood, recent
advancements have linked a number of viruses (e.g. sim-
ian virus 40 T, Epstein–Barr virus andKaposi’s sarcoma-
associated herpes virus), to the deregulation of DNMT
family members through diverse mechanistic pathways,
ultimately leading to methylation-based silencing or
down-regulation of host cellular genes [6,7,9]. The work
presented by Zheng et al. not only helps to gain a better
understanding of molecular mechanisms of HBV: infec-
tion-related epigenetic aberrations, but also suggests that
viral pathogens, in general, may promote carcinogenesis
through similar epigenetic pathways.
Unlike genetic events, epigenetic events are revers-
ible and hence hold better promise for therapeutic
interventions. DNA-methyltransferase inhibitors and
histone deacetylase inhibitors are already available asdrugs to cure diﬀerent cancers and are showing prom-
ising results. However, many of these epigenetic modu-
lator drugs lack isoenzyme selectivity and thus are
limited in their therapeutic value, due to their requiring
high doses, resulting in toxic eﬀects. Findings in the
present study indicate that DNMT3A and HDAC1
speciﬁcally play a major role in epigenetic aberrations
associated with HBV infection. Hence, it emphasizes
the need for subclass-speciﬁc inhibitors of the epige-
netic modulators, which may further help to narrow
down the design of target-speciﬁc therapeutic strate-
gies, thus reducing any side eﬀects of epigenetic drugs.
Moreover, these ﬁndings once again emphasize the role
of the HBx-protein as a central player in HBV-induced
epigenetic aberrations, contributing to the onset and
progression of HCC. The large time gap between
HBV infection and the onset of HCC, however, sug-
gests that the virus-induced aberrant epigenetic proﬁles
may not be a consequence of any targeted process. It is
possible that epigenetic alterations induced by HBV set
the stage for additional epigenetic as well as genetic
events, which may be triggered by environmental and
lifestyle factors.References
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